JIB-04(NSC693627),JumonjiHistoneDemethylaseInhibitor

JIB-04 (NSC693627, E-isomer) is a potent, selective and cell permeable Jumonji histone demethylase inhibitor. Unlike the other known inhibitors, JIB-04 is not a competitive inhibitor of a-ketoglutarate. It inhibits the demethylase activity of Jumonji enzymes in vitro, with IC₅₀ ~230 nM for  JARID1A (KDM5A), ~440 nM for JMJD2A (KDM4A) and JMJD2B (KDM4B), ~340 nM for JMJD2E (KDM2E), and ~1 µM for JMJD3 (KDM6B) and JMJD2C (KDM4C). JIB-04 blocks Jumonji demethylase activity in cells and consequently inhibits cell growth, without affecting other a-ketoglutarate-dependent hydroxylases or histone-modifying enzymes, especially HDACs. JIB-04 alters transcriptional programs in cancer but not in normal cells, leading to cancer-specific cell death. Importantly, in vivo, JIB-04 lowers histone demethylase activity in tumors, reduces tumor burden and prolongs survival of mice in an aggressive breast cancer model.

How to Use:

• In vitro:  JIB-04 was used at 1 µM final concentration in various in vitro assays.
• In vivo: JIB-04 was administered 2–3 times weekly by IP injection at 110 mg/kg in sesame oil (H358 xenografts) or by gavage in Cremophor EL at 55 mg/kg (A549 xenografts) for 4-6 weeks.

Reference: 

• 1. Wang L, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. (2013) Nat Commun. 4:2035

Products are for research use only. Not for human use.